Hematologic Malignancies Articles | Page 3

Venetoclax Combo Reaches High CR Rate in Older AML Patients
Two-thirds of older patients with acute myeloid leukemia achieved complete responses with the combination of venetoclax (Venclexta) and cytarabine.
Ruxolitinib Retains Benefit in Polycythemia Vera With Longer Follow-Up
Responses to ruxolitinib (Jakafi) in patients with polycythemia vera were maintained by a majority of primary responders at 4 years’ follow-up.
NICE Recommends Ixazomib for Multiple Myeloma Through CDF
The United Kingdom's National Institute for Health and Care Excellence has issued guidance recommending ixazomib in for patients with relapsed/refractory multiple myeloma.
FDA Approves Bosutinib for Newly-Diagnosed Ph+ CML
The FDA has approved bosutinib as a first-line treatment for patients with Philadelphia chromosome-positive chronic myeloid leukemia.
Selinexor Highly Active in Relapsed/Refractory AML
Almost half of patients with relapsed/refractory acute myeloid leukemia achieved complete response with the combination of selinexor (KPT-330) and AraC-containing chemotherapy.
NICE Recommends Ibrutinib for Relapsed/Refractory MCL
The United Kingdom's National Institute for Health Care and Excellence has published new guidelines recommending ibrutinib as treatment for patients with relapsed/refractory mantle cell lymphoma.
Selinexor Combo Highly Active in Relapsed/Refractory Myeloma
Selinexor combined with weekly bortezomib and low-dose dexamethasone produced rapid and durable responses in a dose escalation/expansion trial of patients with relapsed/refractory multiple myeloma.
Promising Results in CLL for Frontline Ibrutinib Plus Chemoimmunotherapy
Adding ibrutinib to a standard frontline chemoimmunotherapy for chronic lymphocytic leukemia induced negative minimum residual disease status in bone marrow for 83% of patients.
Expert Emphasizes Importance of Acalabrutinib Approval in MCL
Michael Wang, MD, discusses the impact of acalabrutinib on patients with mantle cell lymphoma, ongoing progress in the field, and The University of Texas MD Anderson Cancer Center
New Analysis Confirms Carfilzomib Survival Benefit in Relapsed/Refractory Myeloma
The addition of carfilzomib to lenalidomide and dexamethasone for relapsed/refractory multiple myeloma led to a statistically significant 21% reduction in the risk for death compared with lenalidomide and dexamethasone.
Publication Bottom Border
Border Publication